388 related articles for article (PubMed ID: 19067498)
1. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
2. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.
Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
Circulation; 2007 Apr; 115(16):2128-35. PubMed ID: 17420348
[TBL] [Abstract][Full Text] [Related]
3. Impact of statin copayments on adherence and medical care utilization and expenditures.
Gibson TB; Mark TL; Axelsen K; Baser O; Rublee DA; McGuigan KA
Am J Manag Care; 2006 Dec; 12 Spec no.():SP11-9. PubMed ID: 17173486
[TBL] [Abstract][Full Text] [Related]
4. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.
Motheral BR; Henderson R
Am J Manag Care; 1999 Nov; 5(11):1383-94. PubMed ID: 10662412
[TBL] [Abstract][Full Text] [Related]
5. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
[TBL] [Abstract][Full Text] [Related]
6. The effects of prescription drug copayments on statin adherence.
Gibson TB; Mark TL; McGuigan KA; Axelsen K; Wang S
Am J Manag Care; 2006 Sep; 12(9):509-17. PubMed ID: 16961440
[TBL] [Abstract][Full Text] [Related]
7. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.
Ye X; Gross CR; Schommer J; Cline R; St Peter WL
Clin Ther; 2007 Dec; 29(12):2748-57. PubMed ID: 18201593
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice.
Willey VJ; Reinhold JA; Willey KH; Kelly BL; Cziraky MJ
Int J Clin Pract; 2010 Aug; 64(9):1235-8. PubMed ID: 20653799
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
[TBL] [Abstract][Full Text] [Related]
10. Impact of decreasing copayments on medication adherence within a disease management environment.
Chernew ME; Shah MR; Wegh A; Rosenberg SN; Juster IA; Rosen AB; Sokol MC; Yu-Isenberg K; Fendrick AM
Health Aff (Millwood); 2008; 27(1):103-12. PubMed ID: 18180484
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
12. Are patent expirations the answer to improving patient adherence?
Klepser DG
Am J Manag Care; 2008 Dec; 14(12):787-8. PubMed ID: 19067495
[No Abstract] [Full Text] [Related]
13. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
14. Moving from A to Z: successful implementation of a statin switch program by a large physician group.
Sy FZ; Choe HM; Kennedy DM; Standiford CJ; Parsons DM; Bruhnsen KD; Stevenson JG; Bernstein SJ
Am J Manag Care; 2009 Apr; 15(4):233-40. PubMed ID: 19355796
[TBL] [Abstract][Full Text] [Related]
15. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit.
Rodin HA; Heaton AH; Wilson AR; Garrett NA; Plocher DW
Am J Manag Care; 2009 Dec; 15(12):881-8. PubMed ID: 20001169
[TBL] [Abstract][Full Text] [Related]
16. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications.
Maciejewski ML; Bryson CL; Perkins M; Blough DK; Cunningham FE; Fortney JC; Krein SL; Stroupe KT; Sharp ND; Liu CF
Am J Manag Care; 2010 Jan; 16(1):e20-34. PubMed ID: 20059288
[TBL] [Abstract][Full Text] [Related]
17. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
Bottorff MB; Yenkowsky JP; Cave DG
Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
[TBL] [Abstract][Full Text] [Related]
18. Effect of statin adherence on cerebrovascular disease in primary prevention.
Perreault S; Ellia L; Dragomir A; Côté R; Blais L; Bérard A; Lalonde L
Am J Med; 2009 Jul; 122(7):647-55. PubMed ID: 19559167
[TBL] [Abstract][Full Text] [Related]
19. Effect of tiered prescription copayments on the use of preferred brand medications.
Rector TS; Finch MD; Danzon PM; Pauly MV; Manda BS
Med Care; 2003 Mar; 41(3):398-406. PubMed ID: 12618643
[TBL] [Abstract][Full Text] [Related]
20. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations.
Pittman DG; Chen W; Bowlin SJ; Foody JM
Am J Cardiol; 2011 Jun; 107(11):1662-6. PubMed ID: 21439533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
